| Cash Flow | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|
| Net loss | -19,773,114 | -17,922,621 | -15,941,328 |
| Amortization of debt discount | 2,021,209 | - | - |
| Loss on extinguishment of debt | -364,109 | -364,109 | - |
| Change in fair value of derivative liabilities | 390,744 | -384,318 | -94,917 |
| Interest expense | - | 817,824 | 289,931 |
| Stock based compensation | 14,131,250 | 14,131,250 | 14,131,250 |
| Prepaid expenses | 190,065 | 553,833 | 389,615 |
| Inventory | 35,437 | - | - |
| Due from related party | - | 1,027,920 | 1,027,920 |
| Accounts payable | -277,250 | 1,041,420 | 1,121,806 |
| Accrued expenses | 265,421 | -15,359 | 80,457 |
| Other current liabilities | -111,026 | -111,026 | -111,026 |
| Net cash flows provided by (used in) operating activities | -3,995,647 | -2,891,838 | -1,751,528 |
| Issuance of common stock | - | 0 | 0 |
| Proceeds from recapitalization | 265,827 | 265,828 | 265,828 |
| Proceeds from issuance of convertible notes | 10,250,000 | 3,000,000 | 3,000,000 |
| Repayment of convertible notes | 3,032,645 | - | - |
| Repayment of subscription agreement loan | 483,474 | - | - |
| Transaction costs paid in connection with convertible notes | 907,499 | - | - |
| Proceeds from notes payable - related party | 50,000 | 50,000 | 50,000 |
| Repayment of notes payable related party | 201,924 | 221,390 | 221,390 |
| Net cash flows provided by (used in) financing activities | 5,940,285 | 3,094,438 | 3,094,438 |
| Net change in cash | 1,944,638 | 202,600 | 1,342,910 |
| Cash and cash equivalents at beginning of period | 3,633 | - | - |
| Cash and cash equivalents at end of period | 1,948,271 | - | - |
Aspire Biopharma Holdings, Inc. (ASBPW)
Aspire Biopharma Holdings, Inc. (ASBPW)